I-BRD9 (GSK602) is a potent and selective BRD9 inhibitor with pIC50 of 7.3, while it displayed a pIC50 of 5.3 against BRD4.

Cyclo(-RGDfK) TFA is the salt product of Cyclo(-RGDfK) and trifluoroacetic acid (TFA). The addition of TFA enhances stability and biocompatibility. Cyclo(-RGDfK) TFA effectively targets tumor microvessels and cancer cells by specifically binding to the cell surface Integrin αvβ3.

Cyclo(-RGDfK) TFA is the salt product of Cyclo(-RGDfK) and trifluoroacetic acid (TFA). The addition of TFA enhances stability and biocompatibility. Cyclo(-RGDfK) TFA effectively targets tumor microvessels and cancer cells by specifically binding to the cell surface Integrin αvβ3.

OICR-9429 is a potent antagonist of the interaction of WDR5 with peptide regions of MLL and Histone 3 and reduces viability of acute myeloid leukemia cells in vitro. It binds to WDR5 with high affinity (KD = 93 ± 28 nM.

OICR-9429 is a potent antagonist of the interaction of WDR5 with peptide regions of MLL and Histone 3 and reduces viability of acute myeloid leukemia cells in vitro. It binds to WDR5 with high affinity (KD = 93 ± 28 nM.

OICR-9429 is a potent antagonist of the interaction of WDR5 with peptide regions of MLL and Histone 3 and reduces viability of acute myeloid leukemia cells in vitro. It binds to WDR5 with high affinity (KD = 93 ± 28 nM.

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.

MI-463 is a potent inhibitor of Menin-MLL interaction with an IC50 value of 15.3 nM.

MI-463 is a potent inhibitor of Menin-MLL interaction with an IC50 value of 15.3 nM.

AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.